ABSTRACT

Introduction

Cell-based delivery systems offer considerable promise as novel and innovative therapeutics to target the respiratory system. These systems consist of cells and/or their extracellular vesicles that deliver their contents, such as anti-microbial peptides, micro RNAs, and even mitochondria to the lung, exerting direct therapeutic effects.

Areas covered

The purpose of this article is to critically review the status of cell-based therapies in the delivery of therapeutics to the lung, evaluate current progress, and elucidate key challenges to the further development of these novel approaches. An overview as to how these cells and/or their products may be modified to enhance efficacy is given. More complex delivery cell-based systems, including cells or vesicles that are genetically modified to (over)express specific therapeutic products, such as proteins and therapeutic nucleic acids are also discussed. Focus is given to the use of the aerosol route to deliver these products directly into the lung.

Expert opinion

The use of biological carriers to deliver chemical or biological agents demonstrates great potential in modern medicine. The next generation of drug delivery systems may comprise ‘cell-inspired’ drug carriers that are entirely synthetic, developed using insights from cell-based therapeutics to overcome limitations of current generation synthetic carriers.

中文翻译：

---

细胞及其产物在呼吸道药物输送中的作用：过去，现在和将来。

摘要

介绍

基于细胞的递送系统作为靶向呼吸系统的新颖和创新疗法提供了可观的前景。这些系统由细胞和/或其细胞外囊泡组成，这些细胞和/或细胞外囊泡将其内含物（例如抗微生物肽，微小RNAs甚至线粒体）输送到肺部，发挥直接的治疗作用。

覆盖区域

本文的目的是批判性地审查基于细胞的疗法在肺部治疗中的地位，评估目前的进展，并阐明这些新方法的进一步发展面临的主要挑战。概述了如何修饰这些细胞和/或其产物以增强功效。还讨论了更复杂的基于细胞的递送系统，包括经过基因修饰以（过度）表达特定治疗产品（例如蛋白质和治疗性核酸）的细胞或囊泡。重点是使用气雾剂途径将这些产品直接输送到肺中。

专家意见

在现代医学中，使用生物载体来输送化学或生物制剂显示出巨大的潜力。下一代药物输送系统可能包含完全“合成”的“细胞启发性”药物载体，这些药物载体是利用基于细胞的疗法获得的见识开发出来的，以克服现代合成载体的局限性。